Despite advances in treatment for inflammatory bowel disease, more than 55% of patients report medication delays, mostly due ...

Persistent care barriers may lead patients with inflammatory bowel disease (IBD) to ration medication or skip doses. The ...

A four year-long research study has found that particles secreted by an intestinal worm may assist in treating inflammatory ...

The most common reason for delaying or not receiving care was not getting an appointment when they needed one, cited by 39% of respondents. More than half (56%) of patients reported delays in ...

and precision medicine approaches to target improved efficacy and convenience in the treatment of IBD and other immune-mediated diseases, today announced that Spyre's independent Compensation ...

To present the pioneering concept, Peer and his team encoded the anti-inflammatory protein interleukin-10 into mRNA and ...

Taken together, these studies suggest that a proportion of patients with IBD benefit in relation to health-related quality of life and mood disorders from a cognitive–behavioral approach ...

ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) including ulcerative colitis, today announced that it had ...

A two-step approach, including a two-year pause, could quickly cut red tape and provide enough time to thoroughly revise the CS3D, CSRD and EU taxonomy. Disclaimer - All opinions in this column ...

The deal includes an undisclosed upfront payment from BMS, with GentiBio also in line to receive milestone payments of up to $1.9 billion, as well as royalties on any future sales.

“Scott’s research holds promise not only for improving preterm labor treatment but also for advancing pharmacological approaches to other maternal health conditions,” said Justin Legleiter, chair of ...